Chronic myeloid leukemia stem cells.

Area of Science:

• Hematology
• Molecular Oncology
• Stem Cell Biology

Background:

• Chronic myeloid leukemia (CML) is characterized by excessive myeloid cell production.
• CML can progress from a chronic phase to a fatal blast crisis, even with therapy.
• The BCR-ABL fusion gene and its tyrosine kinase activity are central to CML pathogenesis.

Purpose of the Study:

• To investigate the role of hematopoietic stem cells (HSCs) and progenitor cells in CML.
• To understand the genetic and epigenetic factors driving therapy resistance and disease progression.
• To explore therapeutic strategies targeting aberrant stem cell pathways.

Main Methods:

• Review of molecular pathogenesis of CML.
• Investigation of HSC and progenitor cell-specific effects of CML mutations.
• Analysis of genetic and epigenetic events in CML stem and progenitor cells.

Main Results:

• BCR-ABL mutations initiate CML by causing aberrant stem cell differentiation and survival.
• This leads to expanded progenitor populations with self-renewal capacity, generating leukemia stem cells (LSCs).
• Quiescent CML stem cells can serve as a reservoir for disease progression.

Conclusions:

• Targeting molecular pathways driving aberrant progenitor differentiation, survival, and self-renewal is essential.
• Early therapeutic intervention before LSC predominance may prevent blast crisis transformation.
• Understanding HSC-driven CML pathogenesis is key to developing more effective treatments.